Biotech | July 08, 2025
Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
Subscribe To Our Newsletter & Stay Updated
